Clinical Significance Of Measurement Of Serum Insulin-Like Growth Factor Ⅱ Levels In Patients With Cervical Cancer

Cervical cancer is a disease that threaten the health of women severely, which has high incident, mortality and early age of incident. The early diagnosis and therapy of cervical cancer is concerned widely more and more. Insulin-like growth factor II (IGF-II) is a member of insulin-like growth factor system, which is a growth factor with many function. It control the apoptosis, incident and development of cancer, which is a important factor to promote the proliferation of cancer cell. It has been reported that IGF-II is over expressed in many types of cancer tissues, including cervical cancer. Cancer cell can secreted IGF-II by autocrime, the loss of imprinting of IGF-II gene and the loss of IGF-IIR gene also can make the serum level of IGF-II increasing. The the serum level of IGF-II of cervical cancer is also increased. It is a new approach to study the pathogenesis, diagnosis and therapy of cervical cancer. We measur the IGF-II serum levels of controls, the patient of CINand cervical cancer pre~,post- therapy, and we analyze the serum IGF-II levels' association with the clinical stages and therapy efficacy of cervical cancer. We aimed to further document that the serum IGF-II levels are associated with the oncogenesis-,prognosis and therapy efficacy of cervical cancer.Object To investigate the relationship between serum insulin-like growth factor II (IGF-II) levels and the oncogenesis^prognosis and therapy efficacy of cervical cancer.Method The serum from 12 controls, 16 cases of CIN before therapy, 45 cases of cervical cancer before therapy, 13cases of cervical cancer for 6 months after therapy and 20 cases of cervical cancer for 18 months after therapy, altogether 106 serums, were used to measur IGF-II levels in ELISA kit. Statistical methods were used to analyze and compare the datum between the three groups and among the patient group.Results The levels of serum IGF-II in women with cervicalcancer (527. 32 + 90. 98ng/ml) were increased significantly thanthose in women with CIN (385.28±85.05 ng/ml) and controls(314. 11 + 98. 14 ng/ml) (P < 0. 01). The positive rate of elevatedserum IGF-II levels in cervical cancer (39/45,86.67%) and CIN (9/16,56.25%) was signi- -ficantly higher than controls (0/12, 0 %) (P < 0. 01). The serum IGF-II levels had no correlation with the different grade of CIN; The serum IGF-II levels were increased with the increase of the clinical stages of cervical cancer, and had positive correlation with the clinical stages of cervical cancer (P< 0.05).The serum IGF-II levels were not higher in cervical cancer with lymphatic metastasis than that without lymphatic metastasis;the serum IGF-II levels in high\middle differentiation patients was probably the lowest in cervical cancer. Compared to before therapy , the serum IGF-II levels were decreased significantly after therapy (P < 0. 05). We may deduce that IGF-II is a new tactics in the therapy of cervical cancer by reducing the serum IGF-II levels or weakening the effect of IGF-II.Conclusion U The levels of serum IGF-II in women with cervical cancer were significantly increased ,the positive rate of elevated serum IGF-II levels in controls % CIN and cervical cancer was gradually increased , which suggested Serum...